Graft Versus Host Disease Clinical Trial
Verified date | October 2003 |
Source | Office of Rare Diseases (ORD) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
OBJECTIVES: I. Determine the efficacy of unrelated donor hematopoietic stem cell
transplantation in the treatment of patients with life threatening hemophagocytic disorders.
II. Determine the rate of disease free survival, incidence of graft failure, and incidence
of graft versus host disease in these patients after undergoing this treatment regimen.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 55 Years |
Eligibility |
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Patients diagnosed with any of the following active but stable, or nonactive/quiescent, hemophagocytic disorders: - Hemophagocytic lymphohistiocytosis (HLH) - Fever greater than 38.5 degrees Celsius - Splenomegaly (greater than 3 cm below costal margin) - Hemophagocytosis in bone marrow or spleen or lymph nodes - Disease may be confirmed by positive family history - No evidence of malignancy - Hypertriglyceridemia and/or hypofibrinogenemia - Fasting triglycerides at least 2.0 mmol/L or at least 3 standard deviations above normal for age - Fibrinogen no greater than 1.5 g/L or no greater than 3 standard deviations above normal - Cytopenia (affecting at least 2 of 3 lineages in the peripheral blood) - Hemoglobin less than 9.0 g/L - Platelet count less than 100,000/mm3 X-linked lymphoproliferative disorder (XLP) Two or more maternally related males manifesting at least one of the following XLP phenotypes: - Fulminant infectious mononucleosis - Dysgammaglobulinemia - Malignant lymphoma/lymphoproliferative disorder - Aplastic anemia - Lymphoid granulomatosis/vasculitis OR - A maternally related male in an established XLP kindred who has strong genetic (RFLP) linkage to the XLP locus Chediak-Higashi syndrome Partial oculocutaneous albinism (hair, skin, eyes) Frequent bacterial infections Large peroxidase positive granules in leukocytes of peripheral blood or bone marrow Positive family history or parental consanguinity is supportive of the diagnosis May not have entered accelerated phase as defined by any of the following: - Lymphadenopathy - Pancytopenia - Histiocytes with hemophagocytosis in bone marrow, lymph nodes, liver, or spleen Viral associated hemophagocytic syndrome (VAHS) Relapsed after prior therapy or supportive care Diagnostic criteria as for HLH No hemophagocytic disorders secondary to underlying malignancy Patients 35 years of age and under must have a hematopoietic stem cell donor that is one of the following: - HLA A and B identical OR - Single HLA A or B serologic mismatch with DRB1 identity OR - HLA A or B serologic identity with a single DRB1 mismatch Patients 36 to 55 years of age must have a hematopoietic stem cell donor that is one of the following: - HLA A and B and HLA DRB1 identical OR - Single HLA A or B serologic mismatch with DRB1 identity Patients receiving umbilical cord blood must have an unrelated donor with no more than two antigen HLA A, B, or DRB1 mismatches --Patient Characteristics-- Performance status: Karnofsky 70-100% OR Age less than 16 years: Lansky 50-100% Life expectancy: Not severly limited by another disease Hepatic: SGOT less than 3 times normal Bilirubin less than 2.5 mg/dL Renal: Creatinine normal OR Creatinine clearance or glomerular filtration rate greater than 50% normal Cardiovascular: If symptomatic, ventricular ejection fraction must be greater than 40% and must improve with exercise OR Shortening fraction normal on echocardiogram Pulmonary: - If symptomatic, DLCO greater than 45% predicted (corrected for hemoglobin) - In children unable to perform pulmonary function testing, oxygen saturation must be greater than 95% Other: HIV negative No significant active infections |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Fairview University Medical Center | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Fairview University Medical Center |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03357159 -
Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Recruiting |
NCT01385124 -
Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01616680 -
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease
|
Phase 2 | |
Recruiting |
NCT01810926 -
T&B Depletion Non Malignant
|
Phase 2 | |
Completed |
NCT01379209 -
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
|
Phase 1/Phase 2 | |
Completed |
NCT01233921 -
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
N/A | |
Recruiting |
NCT00986557 -
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
|
Phase 2 | |
Enrolling by invitation |
NCT00972660 -
Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease
|
Phase 2 | |
Terminated |
NCT00555048 -
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT00373815 -
Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease
|
Phase 1 | |
Terminated |
NCT00608517 -
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
|
N/A | |
Completed |
NCT00056875 -
Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants
|
Phase 1/Phase 2 | |
Recruiting |
NCT05808985 -
Intestinal Microbiome-based Research for the Prevention of Acute GVHD
|
Phase 2 | |
Completed |
NCT00813618 -
Study of MEDI 507 in the Treatment of Pediatric Patients
|
Phase 1 | |
Completed |
NCT00003398 -
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
|
Phase 4 | |
Terminated |
NCT00005641 -
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
|
Phase 2 | |
Completed |
NCT02663622 -
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
|
Phase 2 | |
Completed |
NCT00577278 -
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
|
Phase 2 |